Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity

Abstract

ObjectivesNivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose–response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cell lung cancer (NSCLC).MethodsOutcomes of patients with NSCLC treated with nivolumab as a routine practice at two tertiary hospitals in Korea were retrospectively analysed. Patients who could not afford standard nivolumab treatment received low-dose nivolumab (20 or 100 mg fixed dose every 3 weeks). Others received standard dose of 3 mg/kg every 2 weeks. Progression-free survival (PFS) and overall survival (OS) were measured and compared between low-dose and standard-dose groups in overall and stratified analyses according to programmed death-ligand 1 (PD-L1) status.ResultsAmong the 47 patients with NSCLC, 18 received low-dose nivolumab. PD-L1 positivity was observed in 13 (27.7%) patients and did not differ between the groups. During 5.2 months of follow-up, the objective response rate was 13.8% in the standard-dose group and 16.7% in the low-dose group (p=0.788). Dosing of nivolumab or PD-L1 expression did not significantly affect PFS or OS.ConclusionLow-dose nivolumab can be effective in NSCLC and is worth considering as an alternative option to reducing financial toxicity. The efficacy of low-dose nivolumab requires study.

Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis

“…In lung cancer, it is licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Two large randomised studies in patients with advanced non-squamous (NSq) NSCLC (CheckMate057 [3]) and squamous (Sq) NSCLC (CheckMate017 [4]) comparing nivolumab to docetaxel have demonstrated its efficacy at extending overall survival (OS) [5,6], and the interest of nivolumab in treating NSCLC has been confirmed in many subsequent studies in routine clinical practice [7][8][9][10][11][12][13][14][15][16][17][18].…”

How Mathematical Modeling Could Contribute to the Quantification of Metastatic Tumor Burden Under Therapy: Insights in Immunotherapeutic Treatment of Non-Small Cell Lung Cancer

“…The tumor size distributions shown in Figure 3 for patient KE-02 confirm this approach quantitatively. Another aspect is to optimize the dosage of Nivolumab, as it has been shown that low-dose Nivolumab could have comparable efficacy on cancer patients due to its flat dose-response relationship [50]. The flat relationship is mapped by the values of c 50 i , the drug concentrations yielding half-maximal response, that are by far lower than the body concentration steady states of the drugs when applied (cf.…”

Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response

“…It has been suggested that nivolumab could be a candidate for dose reduction 82 . No randomised trial data or regulatory authority supports ICB dose modification, but retrospective real‐world evidence in resource poor settings has found that low‐dose nivolumab (20–100 mg Q3W) had similar efficacy in a metastatic NSCLC cohort 101 …”